Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.

Tytuł:: Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.
Autorzy:: Griffin AJ; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
O'Donnell KL; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
Shifflett K; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
Lavik JP; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Russell PM; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Zimmerman MK; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Relich RF; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA. .
Źródło:: Scientific reports [Sci Rep] 2022 Mar 10; Vol. 12 (1), pp. 3954. Date of Electronic Publication: 2022 Mar 10.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
Język:: English
Imprint Name(s):: Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:: Broadly Neutralizing Antibodies/*immunology
COVID-19/*virology
SARS-CoV-2/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/immunology ; Chemokines/blood ; Cytokines/blood ; Female ; Humans ; Male ; Middle Aged ; Patient Acuity ; Young Adult
References:: JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
N Engl J Med. 2021 Aug 12;385(7):664-666. (PMID: 34233096)
Nature. 2021 Dec;600(7889):523-529. (PMID: 34634791)
Clin Infect Dis. 2020 Jul 28;71(15):762-768. (PMID: 32161940)
Nature. 2021 Aug;596(7871):276-280. (PMID: 34237773)
Clin Immunol. 2020 May;214:108408. (PMID: 32247038)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
Cell. 2021 Apr 29;184(9):2372-2383.e9. (PMID: 33743213)
Cell. 2020 Dec 10;183(6):1496-1507.e16. (PMID: 33171099)
Nature. 2020 Oct;586(7830):578-582. (PMID: 32731258)
PLoS Biol. 2021 Apr 29;19(4):e3001237. (PMID: 33914735)
Virol J. 2021 Oct 29;18(1):211. (PMID: 34715884)
Nature. 2021 Jan;589(7843):500-501. (PMID: 33479534)
J Leukoc Biol. 2020 Jul;108(1):17-41. (PMID: 32534467)
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4. (PMID: 32360286)
Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462)
J Leukoc Biol. 2021 Jan;109(1):55-66. (PMID: 32930456)
Autoimmun Rev. 2020 Jul;19(7):102567. (PMID: 32376392)
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942. (PMID: 32301997)
Eur J Immunol. 2021 Dec;51(12):3202-3213. (PMID: 34580856)
Sci Rep. 2016 Jan 21;6:19674. (PMID: 26790609)
Cell Mol Immunol. 2020 Jul;17(7):773-775. (PMID: 32467617)
Science. 2021 Mar 12;371(6534):1152-1153. (PMID: 33514629)
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):. (PMID: 34417349)
Nat Med. 2021 May;27(5):917-924. (PMID: 33772244)
N Engl J Med. 2021 May 13;384(19):1866-1868. (PMID: 33761203)
Cell Mol Immunol. 2020 Oct;17(10):1095-1097. (PMID: 32895485)
J Clin Immunol. 2021 Nov;41(8):1733-1744. (PMID: 34570326)
Am J Respir Crit Care Med. 2013 Jan 1;187(1):65-77. (PMID: 23144331)
Emerg Infect Dis. 2020 Jun;26(6):1266-1273. (PMID: 32160149)
Int J Infect Dis. 2021 Nov;112:227-234. (PMID: 34536610)
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9. (PMID: 33259788)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4. (PMID: 32425269)
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32. (PMID: 22390970)
Nat Biomed Eng. 2020 Dec;4(12):1134-1139. (PMID: 33293725)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Autoimmun Rev. 2020 Jun;19(6):102537. (PMID: 32251717)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)
Cell. 2020 Sep 17;182(6):1419-1440.e23. (PMID: 32810438)
J Interferon Cytokine Res. 2020 Jan;40(1):19-23. (PMID: 31755797)
Emerg Microbes Infect. 2020 Dec;9(1):2091-2093. (PMID: 32930052)
Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096)
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. (PMID: 32320677)
Nature. 2021 Jul;595(7867):426-431. (PMID: 34126625)
Med (N Y). 2021 Mar 12;2(3):313-320.e4. (PMID: 33554155)
Nature. 2021 May;593(7857):136-141. (PMID: 33706364)
PLoS Pathog. 2022 Feb 8;18(2):e1010248. (PMID: 35134084)
Grant Information:: 100006492 United States ImNIH Intramural NIH HHS
Substance Nomenclature:: 0 (Broadly Neutralizing Antibodies)
0 (Chemokines)
0 (Cytokines)
SCR Organism:: SARS-CoV-2 variants
Entry Date(s):: Date Created: 20220311 Date Completed: 20220317 Latest Revision: 20220317
Update Code:: 20240104
PubMed Central ID:: PMC8913826
DOI:: 10.1038/s41598-022-07960-4
PMID:: 35273264
: Czasopismo naukowe

Pełny tekst

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the extent to which a patient responded to a pathogen. We examined serum and plasma from a cohort of patients infected with SARS-CoV-2 early in the pandemic and compared them to negative-control sera. Cytokine and chemokine concentrations varied depending on the severity of infection, and antibody responses were significantly increased in severe cases compared to mild to moderate infections. Neutralization data revealed that patients with high titers against an early 2020 SARS-CoV-2 isolate had detectable but limited neutralizing antibodies against the emerging SARS-CoV-2 Alpha, Beta and Delta variants. This study highlights the potential of re-infection for recovered COVID-19 patients.
(© 2022. The Author(s).)

Update of: bioRxiv. 2021 Nov 12;:. (PMID: 34790978)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja